MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM
The Multiple Myeloma Hub spoke with Paul Richardson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, US. We asked about the clinical implications of findings from the phase III MIDAS trial (NCT04934475), which evaluated a measurable residual disease (MRD)-driven consolidation and maintenance strategy after induction with isatuximab + carfilzomib + lenalidomide + dexamethasone (Isa-KRd) in patients aged less than 66 years with newly diagnosed (ND), autologous stem-cell transplantation (ASCT)-eligible multiple myeloma (MM) (N = 791).
The primary end…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.